Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma

Dongyang Yang | Fei Xu | Ying Li | Xiaorong Lai | Bohong Xian | Pengli Yu | Rongrong Chen | Zijun Li | Dong Ma

1Secondary division of Medical Oncology, Cancer Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
2Department of Medicine, Geneplus-Beijing Institute, Beijing, China
3Department of Gastroenterology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

Correspondence
Zijun Li, PhD, Department of Gastroenterology, Guangdong Academy of Medical Sciences, Guangdong Provincial People’s Hospital, Guangzhou 510080, China.
Email: zijunli2005@aliyun.com

Dong Ma, MD, Secondary division of Medical Oncology, Cancer Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, No.106, Zhongshan 2nd Road, Guangzhou 510080, China.
Email: dr_madong@163.com

Abstract
Immune checkpoint inhibitor (ICI)-based therapies have shown promising advances for the first-line treatment of advanced or metastatic esophageal cancer (EC). However, few studies concerning the identification of patients who achieve durable response from ICIs have been previously reported. In the present study, pre- and on-treatment plasma circulating tumor DNA (ctDNA) were analyzed in 10 patients with advanced esophageal squamous cell cancer (ESCC) receiving first-line chemoimmunotherapy. Patients with decreased molecular tumor burden index (mTBI) >7% experienced longer progression-free survival (PFS) and durable clinical benefit (DCB, PFS ≥ 6 months). In addition, five patients showed stable disease at first scan, all three patients with decreased mTBI > 7% achieved DCB, while two cases with decreased mTBI ≤ 7% experienced non-DCB. Our results demonstrate that ctDNA monitor might help identify which ESCC patients respond to chemoimmunotherapy.

KEYWORDS
chemoimmunotherapy, circulating tumor DNA, durable response, esophageal squamous cell cancer

INTRODUCTION
Immune checkpoint inhibitor (ICI)-based therapies have recently shown remarkable promising advances for the first-line treatment of advanced or metastatic esophageal cancer (EC). Several PD-1 inhibitors, including pembrolizumab, nivolumab, camrelizumab and toripalimab have been approved for advanced EC in combination with chemotherapy regardless of PD-L1 expression level. However, only a minority of patients benefit from ICI-based therapy. Therefore, the discovery of more precise biomarkers to classify patients who may achieve long-lasting response to immunotherapy is crucial.

Liquid biopsies provide a noninvasive method to detect tumor-derived mutations in the body fluids of cancer patients. Plasma genotyping of circulating tumor DNA (ctDNA) has shown predictive value in assessing recurrence risk in early and localized EC patients. A recent study has shown the early dynamics of ctDNA predict first-line
chemotherapy responses for patients with esophageal squamous cell carcinoma (ESCC). However, few studies have explored the possibility of serial ctDNA analysis for prediction of durable response in ESCC patients receiving ICIs. In this study, we sought to explore whether ctDNA dynamics would enable prediction of response to first-line ICI-based therapy in advanced ESCC.

METHODS

Patients and samples

Patients with stage IV ESCC who had not received systemic treatment were drawn from Guangdong Provincial People’s Hospital. Eligible patients were ≥ 18 years of age with histologically confirmed stage IV ESCC, had received PD-1 blockade together with chemotherapy as first-line therapy, had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, adequate organ and hematological functions, could provide baseline (before initiation of therapy) and/or had on treatment peripheral blood samples available for ctDNA testing. A total of 10 ml of peripheral blood was collected from each patient prior to treatment, and after two to three cycles of therapy. Patients all signed a written consent form prior to the study. Study protocol was approved by the institutional review boards of Guangdong Provincial People’s Hospital (KY-Q-2022-027-01). According to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, we evaluated the clinical response of all patients two to three cycles after treatment initiation (3 weeks/cycle) or whenever there were symptoms or signs indicating disease progression.

| No | Gender | Age | History of smoking | Weight (kg) | ECOG performance status | Sites of metastatic | ctDNA detection timepoints | First-line treatment |
|----|--------|-----|---------------------|-------------|-------------------------|---------------------|--------------------------|---------------------|
| P1 | Male   | 75  | No                  | 62          | 1                       | Multiple lymph nodes in neck and supraclavicular, left adrenal gland metastasis | Baseline, precycle IV | Sintilimab plus docetaxel and cisplatin |
| P2 | Male   | 69  | Yes                 | 59          | 1                       | Bone, posterior wall of left chest | Baseline, precycle IV, precycle VII, Pre-cycle IV, precycle III in monotherapy, | Pembrolizumab plus cisplatin and 5-fluorouracil |
| P3 | Male   | 68  | No                  | 60          | 1                       | Multiple enlarged lymph nodes on both sides of the supraclavicular, left tracheoesophageal groove, retroperitoneum | Pembrolizumab plus cisplatin and 5-fluorouracil |
| P4 | Male   | 50  | No                  | 58          | 1                       | Multiple lymph nodes in the right supraclavicular and right upper mediastinal space | Pembrolizumab plus cisplatin and 5-fluorouracil |
| P5 | Male   | 54  | No                  | 64          | 1                       | Nodules in the right lower lung dorsal segment, left lower lobe basal segment | Pembrolizumab plus docetaxel and cisplatin |
| P6 | Male   | 63  | No                  | 57          | 1                       | Nodules in the mediastinum, left neck, upper and lower left lung | Pembrolizumab plus cisplatin and 5-fluorouracil |
| P7 | Male   | 61  | No                  | 55          | 1                       | Mediastinum, upper lobe of both lungs, middle right lung | Pembrolizumab plus cisplatin and 5-fluorouracil |
| P8 | Male   | 56  | Yes                 | 56          | 1                       | Right thoracic entrance, mediastinum, left hilar, around the cardia, hepatogastric space | Camrelizumab plus docetaxel and cisplatin |
| P9 | Male   | 60  | No                  | 62          | 0                       | Lung | Baseline, precycle IV | Pembrolizumab plus cisplatin and 5-fluorouracil |
| P10 Female | 68 | No | 47 | 1 | Enlarged lymph nodes in the right supraclavicular fossa, cardia, and left stomach | Baseline, precycle IV | Camrelizumab plus docetaxel and cisplatin |

Identification of ctDNA with next-generation sequencing

We performed targeted next-generation sequencing (NGS) of 1021 genes frequently mutated in ESCC (Supplementary Table 1) and other solid tumors. Somatic mutations were identified by paired analysis of plasma ctDNA and germline DNA in blood cells. DNA extraction, library preparation, hybrid capture, sequencing, and analysis were performed as
In brief, targeted capture sequencing required a minimal mean effective depth of 100× in plasma DNA. Genomic alterations, including single nucleotide variants (SNV), small insertions and deletions (indels), copy number alterations (CNA), and gene fusions/rearrangements were detected with GATK, MuTect (version 1.1.4) and BreakDancer, respectively.

**Molecular tumor burden analysis**

We defined the molecular tumor burden index (mTBI) based on a comprehensive analysis of somatic alterations in ctDNA, considering tumor heterogeneity and dynamic evolution, as previously described. The process of mTBI calculation has been carefully described by Yi et al. The ΔmTBI was calculated based on the difference of mTBI between two ctDNA samples collected at different time points.

**Statistical analysis**

Kaplan–Meier survival plots were generated for mTBI at baseline and ΔmTBI using log-rank tests. All statistical analyses were performed with SPSS (version 21.0; STATA) or GraphPad Prism (version 9.0; GraphPad Software) software. Statistical significance was defined as a two-sided p-value of <0.05.

**RESULTS**

Overall, 10 patients with metastatic esophageal squamous cell carcinoma were enrolled in this study. The clinical features and first-line treatments for all patients are shown in Table 1. A total of six, three and one patient received pembrolizumab, camrelizumab and sintilimab based combined therapy, respectively. Treatment-related adverse events of grade 3 or higher occurred in three patients.

Plasma samples obtained from all patients before and during the treatment course underwent targeted NGS. Of these patients, the baseline plasma of P3 failed the NGS test. One patient (P2) had no somatic alteration detected at baseline, and eight patients had at least one alteration detected (range: 1–21 alterations). A total of 66 somatic alterations were detected in baseline samples, including 58 SNVs and eight CNVs. The most commonly detected mutation at baseline was TP53 (6/8, 75%), as shown in Supplementary Table 2. P9 was tumor mutation burden-high (TMB-H) with a TMB value of 21.0 Muts/Mb.

To evaluate whether changes in plasma ctDNA levels could predict a radiographical response to first-line chemoinmunotherapy, mTBI was analyzed. A graphic
summary of treatment, radiographical response and mTBI analysis are shown in Figure 1(a). Half of the patients had radiological stable disease (SD) and the remainder achieved a partial response (PR) at the first radiological scan after treatment initiation. Three experienced progressive disease (PD) during chemoimmunotherapy, while five of them experienced PD during PD-1 monotherapy. As of August 2021, two patients remain on immunotherapy with an ongoing response.

No statistically significant difference in progression-free survival (PFS) was observed between patients with baseline mTBI lower than 3.8 and patients with mTBI equal to or higher than 3.8 (3.8 was the median of baseline mTBI, \( p = 0.643 \); Figure 1(b)).

Nine patients had at least two ctDNA tests. The \( \Delta \)mTBI was calculated based on the difference of mTBI between two ctDNA samples. To assess whether on-treatment ctDNA dynamics could identify which patients will experience a durable benefit from chemoimmunotherapy in the first-line setting, patients were classified into durable clinical benefit (DCB, complete or partial response or stable disease that lasted \( \geq 6 \) months) and NDB (no durable benefit). As shown in Figure 1(c), all six patients with decreased mTBI >7% achieved DCB, while the other three patients with decreased mTBI \( \leq 7\% \) experienced NDB (no durable benefit). As shown in Figure 1(c), all six patients with decreased mTBI >7% achieved DCB, while the other three patients with decreased mTBI \( \leq 7\% \) experienced NDB (no durable benefit). As shown in Figure 1(c), all six patients with decreased mTBI >7% achieved DCB, while the other three patients with decreased mTBI \( \leq 7\% \) experienced NDB (no durable benefit).

Amplifications of chromosome 11q13 region (including CCND1, FGF3/4/19) were detected in on-treatment sample of P1 and baseline and on-treatment samples of P4 (Figure 2). Radiographic scan revealed SD in P1 and P4 after the start of treatment. P1 had increased mTBI, increased copy number of CCND1 and FGF3/4/19, and experienced PFS of 4 months, while P4 achieved decreased mTBI >7%, decreased copy number of CCND1 and FGF3/4/19, and had a PFS of 6 months (Figure 2). P2 and P9 had plasma ctDNA test at disease progression, no acquired mutations were found in P2, while MST1R and MLL3 mutations were newly identified in P9.

**DISCUSSION**

In our study, patients with decreased mTBI >7% were more likely to achieve DCB (PFS \( \geq 6 \) months) than patients with decreased mTBI \( \leq 7\% \), suggesting that ctDNA monitor might help identify responders to chemoimmunotherapy. A phase 2 trial demonstrated that in HER2-positive esophageal cancer, 10/13 patients with decline in ctDNA after the induction cycle of first-line pembrolizumab and trastuzumab were progression-free at 6 months. Similar results were found in NSCLC, which determined the role of early ctDNA changes predicting response to first-line pembrolizumab-based therapy. In those previous studies, one somatic mutation with the highest allele frequency (AF) or mean AF of all genes identified at predose was used to track ctDNA levels over time compared with baseline. mTBI was calculated based on a comprehensive analysis of ctDNA, considering heterogeneity and dynamic evolution. In breast and gastric cancer patients, mTBI had been reported to predict molecular responders to chemotherapy or target therapy. We first used mTBI to predict and
monitor chemoimmunotherapy response. Our results demonstrate that a decrease of mTBI > 7% might help to identify those patients who respond to first-line chemoimmunotherapy in metastatic ESCC.

In addition, the PFS of patients exhibiting stable disease varied over time as the response to ICIs can be delayed. Instead, early ctDNA dynamics may allow more accurate classification of responders compared with first radiographic imaging. In our study, five patients achieved SD as their best radiographic response, three patients with mTBI decrease >7% achieved a PFS ≥ 6 months, while two patients with mTBI decrease ≤7% experienced a PFS of <6 months, demonstrating that monitoring early ctDNA might help identify the patients who really respond to ICIs.

Several studies have demonstrated that compared with radiographic evaluation, serial ctDNA tests could predict treatment failure or recurrence earlier. However, as a result of the lack of repeated plasma samples in the present study, we were unable to estimate the diagnostic lead time between mTBI variations and radiographic evidence of disease progression.

Amplifications of chromosome 11q13 region have been reported to be negative predictive markers in advanced ESCC patients receiving second-line ICI based therapy. One patient in our study had amplification of the 11q13 region and responded to ICI with PFS of 6 months, suggesting patients with this mutation may also benefit from ICI therapy. Plasma sample at disease progression of one patient with baseline TMB-H revealed two acquired mutations, MST1R and MLL3. According to previous studies, colorectal patients with MLL3 mutation could benefit from ICI therapy, while MST1R signaling promoted therapeutic resistance in ESRI mutant breast cancer. Apart from mutations, the tumor immune microenvironment in ESCC, such as PD-L1 expression on tumors and tumor-infiltrating lymphocytes, may also potentially influence the patient’s response to ICIs and should be further investigated.

There are several limitations to our study. The sample size was small, there was an inconsistent timepoint of ctDNA sampling among patients, and not all patients were treated with a uniform chemoinmunotherapy regimen. Larger studies with regular ctDNA sampling are needed to determine whether mTBI decrease after chemoimmunotherapy translates into improved disease-free and overall survival.

In conclusion, the current research indicated that a decrease >7% of ctDNA based mTBI is associated with a better prognosis and response to therapy; therefore, it might be used as a guide in patients with ESCC responding to first-line chemoimmunotherapy. Additional studies with larger sample sizes in this specific patient population and longitudinal plasma ctDNA analysis are warranted to validate these findings.

**AUTHOR CONTRIBUTIONS**

DY Yang, F Xu, D Ma, and Zj Li contributed to the study investigation, writing–review & editing. DY Yang and F Xu contributed to the writing–original draft. DY Yang, F Xu, Y Li and BH Xian contributed to the data curation. XR Lai, PL Yu and RR Chen analyzed the data. D Ma, and Zj Li contributed to the supervision.

**ACKNOWLEDGMENTS**

This work was supported by medical Scientific Research Foundation of Guangdong Province (C20200001), CSCQ-Qilu Oncology Research fund of 2019 (Y-QL2019-0360) and Science and Technology Program of Guangzhou (202102080472).

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ORCID**

Dong Ma @ https://orcid.org/0000-0001-9557-9040

**REFERENCES**

1. Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of Camrelizumab vs placebo to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326:916–25.

2. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced esophageal cancer (KEYNOTE-900): a randomized, placebo-controlled, phase 3 study. Lancet. 2021;398:759–71.

3. Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40:277–288.e3.

4. Ococks E, Sharma S, Ng AWT, et al. Serial circulating tumor DNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection. Gastroenterology. 2021;161:1705–1708.e2.

5. Azad TD, Chaudhuri AA, Fang P, et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology. 2020;158:494–505.e6.

6. Fujisawa R, Iwaya T, Endo F, Igoda M, Sasaki N, Hiroki H, et al. Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer. Cancerogenesis. 2021;42:1239–49.

7. Wang Y, Zhao C, Chang L, Jia R, Liu R, Zhang Y, et al. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019;43:261–9.

8. Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, et al. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020;146:1359–68.

9. Yi Z, Ma F, Gong G, Liu B, Gao Y, Li J, et al. The molecular tumor burden index as a response evaluation criterion in breast cancer. Sig Transduct Target Ther. 2021;6:251.

10. Janjigian YY, Maron SB, Chatila WK, Billang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:821–31.

11. Ricciuti B, Jones G, Severgnini M, et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021;9:e001504.

12. Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysr J, Carriero NJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24:1872–80.
13. Nabetti BY, Esfahani MS, Moding EJ, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020;183:363–376e13.

14. Zhang JT, Liu SY, Gao W, Liu SYM, Yan HH, Ji L, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. 2022;12:1690–701.

15. Tsui DWY, Murtaza M, Wong ASC, et al. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. EMBO Mol Med. 2018;10:e7945.

16. Wang F, Ren C, Zhao Q, et al. Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune checkpoint blockade. J Clin Oncol. 2019;37(15_suppl):4036.

17. Miao C, Zhang X, Ma T, et al. Investigating the potential relationship between KMT2C/KMT2D mutations and immune checkpoint inhibitor (ICI) in colorectal cancer (CRC). Ann Oncol. 2020;31:S451.

18. Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, et al. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer. 2021;124:191–206.

19. Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwatsuki M, Miyamoto Y, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111:3132–41.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Yang D, Xu F, Li Y, Lai X, Xian B, Yu P, et al. Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma. Thorac Cancer. 2022;13(19):2786–91. [https://doi.org/10.1111/1759-7714.14610](https://doi.org/10.1111/1759-7714.14610)